Artikel
Combined Intravitreal Bevacizumab and Triamcinolone for Exudative Age-Related Macular Degeneration
Suche in Medline nach
Autoren
-
Frank C. Schlichtenbrede
- Mannheim/Germany
-
J.B. Jonas
- Mannheim/Germany
-
T. Libondi
- Mannheim/Germany
-
L. Golubkina
- Mannheim/Germany
-
U.H. Spandau
- Mannheim/Germany
-
F. Rensch
- Mannheim/Germany
| Veröffentlicht: | 18. Juni 2008 |
|---|
Gliederung
Text
Purpose: To report on the combined application of intravitreal bevacizumab with triamcinolone acetonide for treatment of exudative age-related macular degeneration.
Design: Clinical interventional case-series.
Methods: The study included 14 patients (14 eyes) with exudative age-related macular degeneration who had previously received 3.7 ± 1.9 mono-injections of bevacizumab (1.5 mg) without improvement in visual acuity or reduction in macular exudation. All patients underwent a combined intravitreal injection of bevacizumab (1.5 mg) and triamcinolone acetonide (about 20 mg). Main outcome measures were visual acuity and macular thickness as determined by optical coherence tomography. All patients were re-examined at 2 to 3 months after the intervention.
Results: Visual acuity improved significantly (P=0.008) from 0.81±0.43 logMAR prior to the combined injection to 0.67±0.41 log MAR. An improvement by at least 1 Snellen line was found for 10 (71%) subjects, an increase by at least 2 lines for 5 (36%) subjects, and an improvement of 3 or more lines for 1 (7%) subject. One patient (7%) lost one line. The central retinal thickness decreased significantly from 255 ± 59 µm to 224 ± 45 µm (P=0.03).
Conclusions: The combined intravitreal application of bevacizumab and triamcinolone may be helpful for the treatment of exudative age-related macular degeneration if previous intravitreal bevacizumab mono-injections failed to improve vision and reduce macular edema.
